PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
G&A reduction while TRAW shows 61301.60% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses change of 264.51% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
3.15%
Operating expenses growth less than half of TRAW's 75603.42%. David Dodd would verify sustainability.
3.15%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
-0.34%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-75.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
15.50%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Other expenses reduction while TRAW shows 1151.26% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense change of 3.90% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
12.65%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth while TRAW declines. John Neff would investigate advantages.
12.55%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.